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Background: Current asthma management guidelines are based on the level of asthma control. The impact of
asthma control on health care resources and quality of life (QoL) is insufficiently studied. EUCOAST study was
designed to describe costs and QoL in adult patients according to level of asthma control in France and Spain.
Methods: An observational cost of illness study was conducted simultaneously in both countries among patients
age greater or equal to 18 with a diagnosis of asthma for at least 12 months. Patients were recruited prospectively
by GPs in 2010 in four waves to avoid a seasonal bias. Health care resources utilization of the three months before
the inclusion was collected through physician questionnaires. Asthma control was evaluated using 2009 GINA
criteria over a 3-month period. QoL was assessed using EQ-5D-3LW.
Results: 2,671 patients (France: 1,154; Spain: 1,517) were enrolled. Asthma was controlled in 40.6% [95% CI: 37.7% -
43.4%] and 29.9% [95% CI: 27.6% - 32.3%] of French and Spanish patients respectively.
For all types of costs, the percentage of patients using health care resources varied significantly according to the
level of asthma control. The average cost (euros/3-months/patient) of controlled asthma was €85.4 (SD: 153.5) in
France compared with €314.0 (SD: 2,160.4) for partially controlled asthma and €537.9 (SD: 2,355.7) for uncontrolled
asthma (p<0.0001). In Spain, the corresponding figures were €152.6 (SD: 162.1), €241.2 (SD: 266.8), and €556.8 (SD:
762.4). EQ-5D-3LW score was higher (p<0.0001) in patients with controlled asthma compared to partially controlled
and uncontrolled asthma in both countries (respectively 0.88; 0.78; 0.63 in France and 0.89; 0.82; 0.69 in Spain).
Conclusions: In both countries, patients presenting with uncontrolled asthma had a significantly higher asthma
costs and lower scores of Qol compared to the others.
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Asthma is a chronic disease with an estimated 300 mil-
lion affected individuals throughout the world [1,2]. In a
large French 2006 survey, 10.2% of a general population
sample declared having suffered from asthma at least
once in their life time and 6.7% had asthma at the time
of the survey [3]. In Spain, the European Community
Respiratory Health Survey (ECRHS-II) showed that the
prevalence of asthma was 7% in some regional popula-
tions in 2007 [4].* Correspondence: bruno.detournay@cemka.fr
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reproduction in any medium, provided the orThe recent publication from the Global Initiative for
Asthma (GINA) updated international guidelines and
highlighted the importance of achieving and maintaining
control as a goal of treatment [1,5]. Standardized tools
[6-9] have been developed to assess asthma control.
Until now, some studies on asthma control based on
data from large samples of asthmatic patients have
already been published in Europe [10,11]. However, such
studies were based on definitions of control that do not
correspond to those of current GINA criteria. Moreover,
asthma control was assessed over various periods of
time (weeks/months) without taking into account symp-
toms seasonality [12].
Poor control of asthma may result in adverse clinical
outcomes as well as substantial economic costs [13].. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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euros in France [14] and between 0.9 and 1.2 billion
euros in Spain [15]. In 2006, the French ESPS survey
estimated that the mean per-patient annual cost of ambu-
latory care was 1.6 times higher in partially controlled,
and 2.9 times higher in uncontrolled asthma as compared
to controlled asthma [16] but few European studies have
provided data on costs related to asthma control. Finally,
uncontrolled asthma may also have a negative impact
on patient’s quality of life [17]. Data from the ECRHS-
II showed that in patients with a known diagnosis of
asthma, respiratory symptoms are important determi-
nants of reduced health related quality of life (HRQL)
[18]. Nevertheless, the specific relation between levels of
asthma control and quality of life has been poorly docu-
mented [19-21].
Consequently, the EUCOAST (EUropean COst of
ASthma Treatment) study was designed to assess utilisa-
tion of healthcare resources, costs and HRQL in adult
patients with asthma in a real life setting in France and
Spain accordingly to the level of asthma control.
Methods
Study design
An observational study was conducted in primary care
settings in France and Spain in order to estimate the so-
cietal costs and the HRQL according to the level of
asthma control in adult patients.
The study design required a single visit per patient.
Data collection was performed on the three-month
period before the inclusion. To take into account sea-
sonality which has a major impact on asthma in both
countries [12], patients were recruited during a period of
one year in four quarterly waves from 01/01/2010 to 12/
31/2010.
The EUCOAST study was approved by the French
Consultative Committee for the data processing in
health research (CCTIRS) and by the National commis-
sion for the personal data protection (CNIL). In Spain,
the study obtained the authorisation of the Spanish Agency
of Medicines and Medical Devices (AEMPS) and the
favourable opinion of the Clinical research Ethics Commit-
tee (CEIC) Hospital Clínico y Provincial de Barcelona.
Populations
Patients were included if they met the following inclu-
sion criteria: adults aged 18 or over, diagnosed with
asthma for at least 12 months and having received at
least one anti-asthmatic treatment (whatever the treat-
ment) within the past 12 months.
Exclusion criteria were participation into a clinical trial
during the past 6 months, aged 45 years and over with a
history of smoking of at least 20 pack years, chronic ob-
structive pulmonary disease (COPD) or pregnancy.Based on the percentage of patients with controlled
asthma estimated to represent 40% to 50% of the overall
population in previous studies [22], and knowing that
the size of the sample needed to estimate percentage
with a ± 5% value according to the confidence interval
selected (alpha risk 5%, normal distribution), around 380
patients had to be enrolled quarterly.
In France, investigators were a sample of GPs selected
from a representative panel of 1,200 general practi-
tioners. The panel's representativeness was established
by three criteria: age, sex and region of practice. The
study was proposed to 750 GPs of this panel, randomly
selected and 230 agreed to participate.
In Spain, 105 general practitioners of 18 autonomous
communities belonging to 3 regions (North, South and
Mediterranean) were contacted and 87 agreed to partici-
pate. A territorial representativeness was able to be
obtained when the sample was constituted.
Practitioners had to include patients in the usual con-
text of their practice. To avoid a selection bias, the first
two consecutive patients (the first five in Spain) corre-
sponding to the inclusion/exclusion criteria visiting their
doctor were included in each wave.Data collection
Data collected retrospectively (over the last 3 months)
during the single study visit by the GP were: socio-
demographic characteristics, medical history of patients,
GINA criteria (including occurrences of exacerbations,
limitations of activities, daytime and nocturnal symp-
toms, need of rescue/reliever treatment) and healthcare
resource use due to asthma.
For all medical resources consumption (including sick
leaves) during the 3 months prior to GP visit, data were
provided by GPs through the questionnaires used in the
study. In France some data (i.e. prescription drugs re-
lated to asthma were also collected through the comput-
erized medical files of the GPs).
Force Expiratory Volume in one second (FEV1) was col-
lected only in a single visit (FEV1 was measured by GPs
three times consecutively as recommended by GINA). As
in France and Spain, all investigators were given a digital
device (Mini-Wright™ Digital, Clement Clarke Inter-
national Ltd) which allowed FEV1 measurements.
At the time of the inclusion, patients completed the
EQ-5D-3LW questionnaire comprising a Visual Analog
Scale (VAS). This questionnaire is a generic instrument
[23] which comprises 5 dimensions: mobility, self-care,
usual activity, pain/discomfort and anxiety/depression
and it is widely used to assess HRQL in asthma patients
[24,25]. EQ-5D-3LW health states were valuated using
validated French [26] and Spanish [27] utility value set
available in each country.
Doz et al. BMC Pulmonary Medicine 2013, 13:15 Page 3 of 10
http://www.biomedcentral.com/1471-2466/13/15Data analysis
In France, data were weighted to compensate the dis-
proportion of inclusions observed among the different
quarterly waves. Individual case weights were defined
according to the ratio between the number of inclusions
in wave 1 and the number of inclusions in the subsequent
waves. In Spain, as the number of inclusions was similar
in each wave, it was not necessary to weight the data.
Data analysis was performed for patients for whom
lung function and symptoms of asthma were duly col-
lected in the medical questionnaire. According to GINA
2009 criteria, patients were classified in 3 subgroups
(“controlled, “partially controlled” and “uncontrolled”
patients); statistic tests were performed to compare these
3 subgroups.
For categorical variables (age, gender, co-morbidities, ex-
acerbations, smoking status, FEV1, visits, hospitalization,
ambulatory exams, emergency room, drugs, sick leave),
Pearson’s Chi2 test or Fisher’s Exact Test were applied.
For continuous variables (costs, EQ-5D-3LW scores, VAS
score, and number of years with a diagnosed asthma), ana-
lysis of the variance was performed. If the data were not
normally distributed, non-parametric tests were used. The
cost analysis was carried out according to a societal per-
spective and took into account both direct and indirect
costs (costs associated with sick leave). Considering differ-
ences between the Spanish and the French healthcare sys-
tems, it was judged as not relevant to compare cost data
across the two countries. A unit cost was given to each
item according to the tariff currently used in 2010a,b. A
weighted average cost was then calculated. In France, ac-
cordingly to national guidelines, productivity loss was esti-
mated by using the human capital method. The Gross
Domestic Product for the year 2008 was divided by the
number of employed population given by the “Institut Na-
tional de la Statistique et des études économiques”
(INSEE) for the same year. Then, the GDP per capita
(employed population only) was divided by the number of
working days. In Spain the average annual salary was used
and sick leaves were valued by using the average annual
salary divided by the number of working hours in a year
(provided in Instituto Nacional de Estadística). In both
case, results were multiplied by the duration of sick leaves
collected through the survey.
As data were collected on a 3-month period, cost data
were not discounted.
Multivariate regression analyses were performed to
examine the relation between level of asthma control
and the outcomes (direct costs only or HRQL levels).
The costs or HRQL levels were the dependent variable
and control level was the independent (explanatory)
variable.
The Tobit model was used for the relation between
cost and level of asthma control in order to take intoaccount patients with zero costs (i.e., left-censoring of
cost data). Multiple linear regression was used to esti-
mate the effect associated with level of control on
HRQL. The potentially confounding factors taken into
account in the models were sex, age, episodes of exacer-
bation of asthma, prescription of a controller treatment
and follow-up by a lung specialist.
Results
Study population
Two hundred thirty-eight investigators (155 in France
and 83 in Spain) enrolled 2,671 patients (1,154 in France
and 1,517 in Spain), Data on FEV1 or asthma symptoms
were missing for 26 patients in France and 31 in Spain),
and data on HRQL were missing for 310 patients in
France and 51 in Spain (Figure 1). Table 1 presents
characteristics of the study population by country and
according to the level of control.
France
Asthma was considered as controlled over the last 3
months in 40.6% [95% CI: 37.7% - 43.4%], partially con-
trolled in 38.0% [95% CI: 35.2% - 40.8%] and uncon-
trolled in 21.4% [95% CI: 19.1% - 23.8%] of patients.
Among patients with an uncontrolled asthma a higher
percentage of women (66.1% for vs. 62.2% for partially
controlled vs. 54.9% for controlled, p<0.0001) and pa-
tients aged 65 and over (28.2% vs. 20.7% for partially
controlled vs. 17.6% for controlled, p<0.0001) were
observed.
Those with uncontrolled asthma had a higher rate of
depression (p<0.0001) than patients with partially con-
trolled or controlled asthma. Prevalence of allergic rhin-
itis, atopic dermatitis, or gastroesophageal reflux was not
significantly related to asthma control.
Asthma exacerbations occurred for 34.6% of patients
during the last 3 months with an average number of 2.3
(SD: 3.0) episodes/patient with exacerbations/quarter. As
expected, the percentage of patients who had at least
one exacerbation was significantly higher (p<0.0001) in
patients with uncontrolled asthma (62.8%) compare to
partially controlled patients (36.2%) and controlled pa-
tients (18.5%). Overall, 70.4% of patients had a normal
lung function (FEV1 ≥80%): 84.8% of those with con-
trolled asthma vs. 67.8% for partially controlled and
57.2% for uncontrolled asthma (p<0.0001).
Spain
The proportion of patients with controlled, partially con-
trolled and uncontrolled asthma were 29.9% [95% CI:
27.6% - 32.3%], 34.1% [95% CI: 31.6% - 36.5%] and
36.0% [95% CI: 33.6%-38.5%], respectively. The level of
asthma control was lower in Spain than in France
Figure 1 Study populations of analyses.
Doz et al. BMC Pulmonary Medicine 2013, 13:15 Page 4 of 10
http://www.biomedcentral.com/1471-2466/13/15(p<0.001). Patients with controlled asthma were younger
than patients with uncontrolled asthma (p<0.0001).
There was a significant relation between asthma con-
trol and rate of allergic rhinitis, atopic dermatitis, and
gastroesophageal reflux as well as depression with more
frequent comorbidities in patients with uncontrolled
asthma. 43.6% of patients suffered from asthma exacer-
bations during the last 3 months with an average num-
ber of 1.8 (SD1.7) episodes/patient with exacerbations/
quarter: 74.4% of those with uncontrolled asthma, 41.3%
with partially controlled and 9.2% with controlled
asthma.
Overall, 78.7% of patients had a normal lung function
(90.7% of those with controlled vs. 74.4% with partially
controlled vs. 72.0% with uncontrolled asthma).
Health resources consumptions and cost of asthma
France
Detailed analyses showed that, for all types of costs, the
percentage of patients with medical resource consump-
tion varied significantly according to the level of asthma
control (Table 2).
The average per-patient total cost of asthma-related
healthcare was €537.9 in uncontrolled patients, €314.0
in partially controlled patients and €85.4 in controlled
patients (p<0.0001). Antiasthmatic drugs represented the
main driver of direct costs, 86.2%, 81.9% and 61.5% in
controlled, partially controlled and uncontrolled pa-
tients, respectively.
Indirect costs were marginal in controlled patients
(4.9% of the total costs) but represented a major driver
in partially controlled and uncontrolled patients (re-
spectively 62.8% and 58.1%) (Table 3).
The multivariate analysis showed that total direct costs
over 3 months were higher in patients with uncontrolled
asthma rather than in patients with controlled asthma (+
€112.8 in uncontrolled patients vs. controlled), olderpeople (≥65) rather than younger ones patients (+€49.),
experiencing exacerbations (+€75.5), treated with con-
troller treatment (+€253.7, or visiting a lung specialist (+
€62.4), (Table 4). Such figures must be interpreted with
caution due to the fact that the level of control may be
the consequence of other covariables (i.e. the controller
treatment).
Spain
The mean per-patient total cost of asthma-related
healthcare was €556.8 in uncontrolled patients, €241.2
in partially controlled patients and €152.6 in controlled
patients (p<0.0001) (Table 3). 92.9% of patients with un-
controlled, as compared with 78.4% of patients with con-
trolled asthma, were prescribed at least one antiasthmatic
drugs during the observation period (p<0.05) (Table 2).
Antiasthmatic medications represented the main
driver of direct costs for controlled and partially con-
trolled asthma (respectively 59.0% and 52.7%) but not
for uncontrolled asthma (36.5%). For the latter GPs visits
had also a major impact on costs accounting for 32.9%
of the mean per-patient direct costs.
Indirect costs were marginal in controlled and in par-
tially controlled patients (respectively 2.6% and 4.7% of
the total costs) but much more important (22%) in un-
controlled patients.
In multivariable analyses, factors predicting asthma
costs were the same in both countries except for gender
which had a significant impact in Spain but not in
France (Table 4).
Quality of life in France and Spain
In both countries (Table 5), average EQ-5D-3LW quality
of life scores were higher for patients with controlled
asthma than patients with partially controlled or uncon-
trolled asthma (0.88 vs. 0.78 vs. 0.63 in France and 0.89
vs. 0.82 vs. 0.69 in Spain; p<0.0001).
Table 1 Characteristics of the asthmatic population in France and Spain according to the level of control
Over a 3-month
period



















Male 45.1% 37.8% 33.9% 38.7% 37.2% 34.2%
Female 54.9% 62.2% 66.1% 61.3% 62.8% 65.8%
Age 0.0132 <0.0001
[18-45[ 40.2% 42.7% 35.6% 60.3% 52.2% 44.8%
[45-65[ 42.2% 36.5% 36.3% 27.7% 25.9% 35.3%
≥65 17.6% 20.7% 28.2% 12.0% 21.9% 19.9%
Mean (SD) 48.4 (16.6) 49.0 (18.0) 53.3 (18.3) 0.0013 42.4 (15.9) 45.6 (19.0) 47.8 (17.7) <0.0001
Number of years with a
diagnosed asthma
Mean (SD) 17.8 (13.7) 19.1 (14.1) 20.9 (14.6) 0.0234 13.2 (10.5) 13.7 (10.4) 15.8 (11.7) 0.0004
Comorbidities (at least
one)
68.8% 73.1% 79.0% 0.0154 72.1% 76.5% 83.1% 0.0002
Allergic rhinitis 70.2% 68.8% 62.4% 0.1668 81.0% 77.0% 70.9% 0.0047
Atopic dermatitis 13.6% 14.2% 19.2% 0.1983 17.4% 18.9% 24.5% 0.0325
Others allergies 15.1% 16.3% 12.0% 0.4036 12.3% 11.1% 13.3% 0.6355
GERD Ŧ 18.9% 24.6% 25.9% 0.1099 12.3% 9.8% 19.4% 0.0002
Depression 12.3% 17.8% 30.0% <0.0001 7.9% 12.7% 16.7% 0.0017
Another disease related
to asthma
6.5% 10.0% 13.0% 0.0453 8.7% 11.1% 9.0% 0.4783
Asthma exacerbations
(last 3 months) Yes
18.5% 36.2% 62.8% <0.0001 9.2% 41.3% 74.4% <0.0001
Smoking status 0.1076 0.0461
Current smoker 14.0% 20.0% 18.7% 13.0% 16.7% 18.8%
Former smoker 17.6% 13.6% 15.4% 18.0% 12.9% 15.4%
Never smoker 68.4% 66.4% 65.9% 69.0% 70.4% 65.9%
Lung function (FEV1∞) <0.0001 <0.0001
<50% 4.7% 8.3% 15.5% 0.9% 5.0% 5.8%
50-79% 10.6% 23.9% 27.3% 8.4% 20.7% 22.1%
≥80% 84.8% 67.8% 57.2% 90.7% 74.4% 72.0%
Ŧ Gastroesophageal reflux disease.
∞ Forced expiratory volume in one second.
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(mobility, autonomy, daily activities, pain/discomfort,
and anxiety/depression) showed consistent differences
between controlled, partially controlled and uncontrolled
patients. For all dimensions, quality of life scores were
better for controlled patients (p<0.0001) (data not
shown).
The Visual Analog Scale (VAS) quality of life scores
were also significantly associated with the level of
asthma control in both countries (p-values < 0.001).
Average VAS scores were 77.33, 70.27, 57.41 in France
and 80.00, 75.13, 62.81 in Spain for controlled, partiallycontrolled and uncontrolled patients, respectively
(Table 5).
In France, using multi-variable regression analyses, the
EQ-5D-3LW scores (Table 6) were significantly lower for
patients having an uncontrolled (estimated value -0.22)
or partially controlled asthma (estimated value -0.09) as
compared with controlled asthma. They were also lower
for female patients and patients aged 65 years or more
(estimated value -0.13) or 45-64 (estimated value -0.07)
rather than those aged 18-44 years.
Similar results were observed in Spain. In addition, in
that country, follow-up by a pulmonary specialist was
Table 2 Asthma associated consumption of medical resources within the last 3 months according to the level of control















% % % p % % % p
At least one prescription
of antiasthmatic drugs
57.9 67.3 71.7 0.0004 78.4 87.7 92.9 <0.0001
Reliever treatment only 6.9 6.8 5.9 0.8583 18.2 16.2 10.8 0.0032
Controller or Reliever and
controller treatment
51 60.5 65.8 0.0003 60.2 71.5 82.1 <0.0001
At least one GP Visit 35.4 44.5 70.0 <0.0001 47.2 64.2 81.9 <0.0001
At least one specialist
visit
2.1 5.1 15.7 <0.0001 11.2 13.8 22.2 <0.0001
At least one
physiotherapist visit
0.2 0.3 3.1 <0.0001 1.1 1.2 4.3 0.0005
At least one nurse visit 0.2 0.4 3.1 <0.0001 5.8 9.7 17.8 <0.0001
At least one emergency
room visit
0 0.7 3.6 <.0001 0.7 2.4 14.4 <0.0001
At least one
hospitalization
0 0 2.1 NA 0 1.0 7.3 <0.0001
At least one ambulatory
exam
2.1 5.6 9.7 <0.0001 27.0 27.5 38.3 <0.0001
At least one sick leave 0.5 2.1 5.3 0.0002 0.7 1.6 13.9 <0.0001
NA Not applicable.
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life (estimated value -0.06; p<0.0003).
Results of the multivariable analysis using the VAS
score as the dependent variable were consistent with
those reported above for the EQ-5D-3LW. In addition,
exacerbations were significantly associated with a lower
VAS score in both countries.
Discussion
In this observational study we found that the proportion
of patients with controlled asthma was significantly
higher in France (41%) than in Spain (30%). In both
countries, costs were higher and HRQL lower as level of
asthma control decreased. The average asthma-related
total health care costs over a three-month period were
€85.4, €314.4 and €537.9 in France and €152.6, €241.2
and €556.8 in Spain for patients with controlled, partially
controlled and uncontrolled asthma, respectively. The
HRQL scores (EQ-5D-3LW) were 0.88, 0.78 and 0.63 in
France (p<0.0001) and 0.89, 0.82 and 0.69 (p<0.0001) in
Spain, for patients with controlled, partially controlled
and uncontrolled asthma, respectively. According to the
GINA 2009 Guidelines [1], the goal of asthma treatment
is to achieve and maintain asthma control. The level
of control is assessed based on symptoms, the use of
reliever treatments, the adaptation of daily life, andmeasurement of peak expiratory flow or FEV1. However,
this assessment of the level of asthma control may be
conducted in different ways and the level of control can
also vary over time.
The GINA 2009 criteria did not specify precisely the
period over which asthma control should be assessed.
Instead, any of the criteria observed over a given week
may affect the level of asthma control for the whole
period. Recently, for the first time, GINA 2010 [28]
guidelines provided a time frame for the assessment of
asthma control and recommended that asthma control
must be assessed “preferably over 4 weeks”. In our study,
asthma control was assessed using symptoms data on a
three-month period but FEV1 was measured only at the
end of that period of time and this may be considered as
a limitation of our study.
Previous studies estimated that approximately 40% of
patients in France [29] have uncontrolled asthma. Simi-
lar figures were observed in Spain [30]. These estimates
are higher than those in our study in France (uncon-
trolled asthma=21.4%) but consistent with our results in
Spain (uncontrolled asthma=36%). However, the differ-
ences between our results and previous ones may be the
consequence of slightly different definitions of asthma
control. The reasons for the differences in asthma con-
trol between the two neighbouring countries are not
Table 3 Mean per-patient asthma-related total cost (euros), societal perspective, according to the level of control GINA
(last 3 months)













Mean (sd) Mean (sd) Mean (sd) p* Mean (sd) Mean (sd) Mean (sd) p*
Antiasthmatic
drugs (€)
70.0 (108.3) 95.7 (141.2) 138.6 (231.4) <0.0001 87.7 (103.9) 121.1 (121.2) 158.4 (141.3) <0.0001
Reliever treatment
only
4.5 (16.6) 8.4 (25.3) 16.4 (49.4) <0.0001 3.6 (13.8) 5.6 (21.8) 13.4 (37.3) <0.0001
Controller treatment 23.0 (61.5) 32.3 (68.6) 50.0 (112.0) 0.0011 24.6 (60.1) 32.5 (65.1) 41.6 (67.9) <0.0001
Fixed association 42.5 (78.4) 55.0 (97.1) 72.2 (118.8) 0.0005 59.5 (77.6) 83.0 (88.4) 103.4 (95.9) <0.0001
GP Visits (€) 9.7 (15.6) 15.8 (26.2) 36.4 (50.6) <0.0001 35.3 (57.7) 71.4 (90.1) 142.9 (148.8) <0.0001
Specialist visits 0.5 (3.6) 2.0 (10.2) 5.7 (14.8) <0.0001 7.5 (22.4) 12.2 (37.5) 23.0 (56.8) <0.0001
Physiotherapist
visits (€)
0.0 (0.6) 0.1 (1.3) 2.5 (19.8) <0.0001 0.3 (2.8) 0.2 (2.2) 1.0 (5.5) 0.0005
Nurse visits (€) 0.0 (0.2) 0.0 (0.5) 0.5 (4.5) <0.0001 1.9 (9.8) 3.2 (12.2) 7.7 (22.5) <0.0001
Emergency
room (€)
0.0 (-) 0.9 (11.5) 4.0 (22.1) <0.0001 0.9 (11.3) 4.1 (29.2) 25.3 (69.2) <0.0001
Hospitalization (€) 0.0 (-) 0.0 (-) 33.6 (227.1) <0.0001 0.0 (-) 3.9 (44.6) 55.3 (268.5) <0.0001
Ambulatory
exams (€)
1.0 (7.3) 2.4 (10.5) 4.0 (13.2) 0.0002 15.0 (32.3) 13.9 (29.9) 20.8 (36.7) 0.0001
TOTAL DIRECT
COST (€)
81.2 (113.3) 116.9 (155.4) 225.3 (352.1) <0.0001 148.7 (147.3) 229.9 (217.3) 434.4 (497.7) <0.0001
Sick leaves (indirect
costs) (€)
4.2 (83.0) 197.1 (2,125.8) 312.6 (2,286.2) 0.0002 3.9 (56.3) 11.3 (109.5) 122.4 (410.7) <0.0001
TOTAL COST (€) 85.4 (153.5) 314.0 (2,160.4) 537.9 (2,355.7) <0.0001 152.6 (162.1) 241.2 (266.8) 556.8 (762.4) <0.0001
*The tests were performed to compare controlled, partially controlled and uncontrolled patients.
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tient compliance with asthma treatments, as well as en-
vironmental and genetic factors. In addition, there may
be measurement issues as physicians may vary in their
assessment of GINA’s criteria.Table 4 Multivariate analyses of asthma related direct costs (
Country
Direct asthma related costs
Level of control measured with GINA Partially controlled (vs. controlled)
Uncontrolled (vs. controlled)
Gender Men vs. women
Age 45-64 years (vs. ≥ 18-44years)
≥ 65 years (vs. ≥ 18-44years)
Presence of exacerbation Yes (vs. None)
Patient with at least one co-morbidity** Yes (vs. None)
Controller treatment Yes (vs. None)
Patient followed by a lung specialist Yes (vs. None)
* p<0.05.
** In France, the most frequent co-morbidity was depression and in Spain it was gaIndeed, an important study found also great varia-
bility in the prevalence of uncontrolled asthma across
European countries [10].
In our study, the average total cost per patient over a
3-month period was higher when asthma was poorly€) (3-month observational period)
France Spain
Estimated Value CI 95% Estimated Value CI 95%
14.6 [-15.1 ; 44.3] 1.4 [-40.1 ; 42.9]
110.9* [74.9 ; 146.8] 104.6* [58.1 ; 151.1]
−19.5 [-45.6; 6.6] 50.9* [18.2 ; 83.6]
39.2* [10.1 ; 68.3] 88.3* [51.5 ; 125.1]
51.3* [17.1 ; 85.5] 79.6* [35.3 ; 123.9]
74.6* [46.5 ; 102.6] 159.8* [122.4 ; 197.2]
26.8 [-2.3 ; 55.9] 11.8 [-26.3 ;49.8]
254.3* [226.9 ; 281.6] 221.6* [184.4 ; 258.7]
59.7* [33.7 ; 85.6] 218.7* [181.0 ; 255.3]
stroesophageal reflux.
Table 5 EQ-5D-3LW scores per level of control
Quality of life according to GINA (last 3 months)
Controlled Partially controlled Uncontrolled p
EQ-5D-3LW score France N 344 307 182
Mean (SD) 0.88 (0.18) 0.78 (0.23) 0.63 (0.28) <0.0001
Spain N 436 498 529
Mean (SD) 0.89 (0.16) 0.82 (0.20) 0.69 (0.24) <0.0001
VAS France N 332 297 171
Mean (SD) 77.33 (15.02) 70.27 (16.74) 57.41 (18.30) <0.0001
Spain N 435 496 528
Mean (SD) 80.00 (14.13) 75.13 (16.17) 62.81 (18.11) <0.0001
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room visits associated costs were higher in patients
with uncontrolled asthma and they represent a higher
percentage of the total direct costs (16.7% and 18.6% of
the total direct cost in France and Spain respectively
versus 0% and 0.6% in patients with controlled asthma).Table 6 Multivariate analyses of EQ-5D-3LW utility score (3-m
Country
EQ-5D-3LW 3L utility score
Level of control measured with GINA Partially controlled (vs.
controlled)
Uncontrolled (vs. controlled)
Gender Men vs. women
Age 45-64 years (vs. ≥ 18-44years)
≥ 65 years (vs. ≥ 18-44years)
Presence of exacerbation Yes (vs. None)
Patient with at least one co-
morbidity
Yes (vs. None)
Controller treatment Yes (vs. None)
Patient followed by a lung specialist Yes (vs. None)
VAS Score
Level of control measured with GINA Partially controlled
(vs. controlled)
Uncontrolled (vs. controlled)
Gender Men vs. women
Age 45-64 years(vs. ≥ 18-44years)
≥ 65 years (vs. ≥ 18-44years)
Presence of exacerbation Yes (vs. None)
Patient with at least one co-
morbidity
Yes (vs. None)
Controller treatment Yes (vs. None)
Patient followed by a lung specialist Yes (vs. None)
* p<0.05.This result is in line with previous European results
[14,16,21].
However, antiasthmatic drugs were the main driver of
direct costs in both countries. In addition, the use of
controller treatment was associated with the highest dir-







−0.093* [-0.128 ; -0.058] −0.042* [-0.068 ; -0.017]
−0.220* [-0.263 ; -0.177] −0.158* [-0.186 ; -0.129]
0.056* [0.019 ; 0.081] 0.052* [0.032 ; 0.072]
−0.071* [-0.105 ; -0.036] −0.101* [-0.123 ; -0.078]
−0.131* [-0.171 ; -0.091] −0.175* [-0.202 ; -0.148]
−0.011 [-0.044 ; 0.024] −0.005 [-0.028 ; 0.017]
−0.019 [-0.053 ; 0.014] −0.028* [-0.051 ; -0.004]
−0.025 [-0.056 ; 0.006] 0.009 [-0.012 ; 0.032]






−5.777* [-8.331 ; -3.223] −2.762* [-4.850 ; -0.675]
−16.758* [-19.959 ; -13.556] −13.255* [-15.609 ; -10.901]
3.456* [1.198 ; 5.714] 2.232* [0.577 ; 3.887]
−5.966* [-8.480 ; -3.453] −8.492* [-10.359 ; -6.625]
−11.179* [-14.140 ; -8.218] −12.258* [-14.507 ; -10.008]
−2.542* [-5.077 ; -0.007] −2.967* [-4.872 ; -1.063]
−3.283* [-5.735 ; -0.831] 0.092 [-1.842 ; 2.027]
−0.749 [-3.037 ; 1.539] 1.788 [-0.064 ; 3.642]
−1.721 [-3.955 ; 0.513] −3.085* [-4.981 ; -1.188]
Doz et al. BMC Pulmonary Medicine 2013, 13:15 Page 9 of 10
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factors (except in the subgroup of Spanish patients with
uncontrolled asthma).
The EUCOAST study presents several limits. First,
both the sampling frame and the sampling method used
did not ensure the representativeness of the investigators
even if their main characteristics were comparable to
those of all French and Spanish GPs.
Secondly, as investigators had to recruit several pa-
tients (until 5 in Spain) there was a potential within-unit
correlation in the data which was not taken into account
in the statistical analysis.
Thirdly, due to a possible short term memory bias GPs
and patients may have under-reported healthcare con-
sumptions. Therefore, costs may be lower than those
found in studies based on claims databases or systematic
healthcare data. However, it is difficult to know whether,
or to what extent, this might have biased our estimates
of the effects associated with level of asthma control. In-
deed, the existence of such bias would depend on
whether under-reporting of costs was differential accor-
ding to level of asthma control.
Costs of medications were based on prescription data.
As some patients may not have been compliant, our esti-
mates may be over-estimates of the true medication-
related costs.
The response rate for the EQ-5D-3LW was lower in
France as compare to Spain (73% vs. 97%). This was
likely the consequence of differences in the HRQL data
collection method in the two countries. In France, pa-
tients were asked to send back their questionnaires to
the study center whereas in Spain most patients com-
pleted the questionnaire in the physician’s office. How-
ever, we did not find significant differences between
responders and non-responders in their level of asthma
control or overall costs.
Conclusion
Asthma control was significantly associated with costs
and health-related quality of life in both France and
Spain. Despite differences in health care systems and
after adjustment for several potentially confounding fac-
tors, in both countries, costs were higher and HRQL
lower as level of asthma control decreased.
These results suggest that implementation of measures
to improve asthma control may improve patients’ quality
of life and reduce related costs for National Health Sys-
tems and for the society.
Endnotes
aIn France: public prices inclusive of tax were used to
get the unit cost of drugs; the rates for all medical and
paramedical procedures were established from national
conventions and from the Common Classification ofMedical Procedures for the year remove one as it is writ-
ten twice 2010.
bIn Spain, the database used for drug costing was that
of the Consejo General de Colegios Oficiales de
Farmacéuticos (http://www.portalfarma.com). For other
resources, costing was carried out using a national Span-
ish base (Spanish Health costs database eSalud).
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